Pelago's new Inpatient Centers of Excellence network offers Pelago members access to a nationwide network of inpatient substance use disorder treatment centers. The network includes organizations like the Recovery Centers of America and Banyan Treatment Centers.
Boulder Care's Series C funding round was led by Advance Venture Partners and included participation from Stripes, First Round Capital, Qiming Venture Partners and Laerdal Million Lives Fund. In total, Boulder Care has raised about $85 million.
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
There needs to be better communication, a focus on clinically appropriate care and more empathy when it comes to treating the mental health of the incarcerated population, executives said during a recent panel discussion.
The DEA proposed a rule back in March that would roll back some of the Covid-19 flexibilities for the virtual prescribing of controlled substances, but has since extended the flexibilities. Stephanie Strong, founder and CEO of Boulder Care, feels confident that the DEA will continue to be open to the prescribing of these medications via telemedicine.
Digital therapeutics developer Click Therapeutics is partnering with Indivior to develop a mobile app for substance use disorder. Indivior is now Click’s third development partner, following deals with Boehringer Ingelheim and Otsuka Pharmaceutical.
There is inadequate substance use disorder support for people who are incarcerated or are leaving incarceration. But there are opportunities to make improvements, experts say.
The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes.
Affect Therapeutics' $16 million Series A funding round was led by ARTIS Ventures and included participation from AlleyCorp, CityLight, LifeArc Ventures, Samsung Next and What If Ventures. In total, Affect Therapeutics has raised about $26 million, said Kristin Muhlner, co-founder and CEO of the company.
Author Health helps seniors with serious mental illness and substance use disorders by working with Medicare Advantage plans. The company launched Wednesday with $115 million in financing, and announced that Humana is its first payer partner.
The DEA recently released proposed rules that would require an in-person visit before a patient can receive a telehealth prescription for a controlled substance. The DEA touts the change as a way to ensure patient safety, but several telehealth advocates argue it will greatly disrupt access for those who need the drugs — especially at a time when the mental health and substance use crisis is growing.
Since the start of the Covid-19 pandemic, there has been a 23% increase in alcohol abuse and a 16% increase in drug abuse, and people in self-isolation reported a 26% higher consumption than usual, according to the National Library of Medicine. Some apps are trying to meet this need, including Sober Sidekick and SoberBuddy.
Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.
There are several trends to watch out for in the substance use disorder space in 2023, according to CHESS Health's CEO Hans Morefield. These trends include rising addiction rates and increased comfort in virtual health.
I write this because of my own personal experience with stealing prescription drugs while employed as a nurse, which led to me serving a four-month jail sentence and losing the career of my dreams.
While telehealth has provided many benefits throughout the pandemic, it can be a lonely and sterile way of receiving treatment. Individuals experiencing substance use disorder who only receive treatment through telehealth may miss opportunities to connect with others in support of the recovery process.
Members of the payer struggling with opioid use disorder can access a full suite of health services offered by Confidant Health that include medication management, therapy, counseling and group support.
Since we know the fundamental causes of the opioid epidemic, why are we still here? It all centers around stigma.